Table 4.
Variable | Treatment |
|||||||
---|---|---|---|---|---|---|---|---|
GC4,5 |
M-VAC27 |
ITP12 |
AG-ITP |
|||||
% | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | |
No. of patients | 203 | 133 | 44 | 60 | ||||
Survival, months | ||||||||
6 | 82 | NR | 83 | 77 to 90 | 95 | 89 to 100 | 88 | 77 to 94 |
12 | 58 | 52 to 65 | 54 | 46 to 63 | 66 | 52 to 80 | 77 | 64 to 85 |
18 | 37 | NR | 37 | 28 to 45 | 54 | 40 to 69 | 45 | 32 to 57 |
24 | 25 | 19 to 31 | 30 | 22 to 37 | 44 | 29 to 59 | 33 | 22 to 45 |
Median survival, months | 14 | 13.4 | 20 | 16.4 | ||||
Progression-free survival, months | ||||||||
Median | 7.7 | 9.6 | 9.6 | 12.1 | ||||
95% CI | 6.8 to 8.8 | 8.0 to 11.0 | 6.5 to 16.3 | 9.0 to 14.8 | ||||
Follow-up, months | ||||||||
Median | NR | 39.8 | 28 | 76.4 | ||||
Range | NR | 0.3-129 | 19-43 | 65-108 |
Abbreviations: M-VAC, methotrexate, vinblastine, doxorubicin, cisplatin; GC, gemcitabine, cisplatin; ITP, ifosfamide, paclitaxel, cisplatin; AG-ITP, doxorubicin, gemcitabine, ifosfamide, paclitaxel, cisplatin; NR, not reported.